Organization
Peloton Therapeutics
5 clinical trials
Clinical trial
An Open Label Phase 2 Study to Evaluate PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell CarcinomaStatus: Completed, Estimated PCD: 2023-08-30
Clinical trial
A Phase 1, Multiple-Dose, Dose-Escalation Trial of PT2385 Tablets, a HIF-2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2017-01-31
Clinical trial
An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2026-03-29
Clinical trial
A Phase 2 Trial of PT2977 in Combination With Cabozantinib in Patients With Advanced Clear Cell Renal Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2025-08-31
Clinical trial
A Phase 1, Dose-Escalation and Expansion Trial of PT2977, a HIF-2α Inhibitor, in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2018-01-12